Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer

Jennifer Parma, Anne Pavlick, Rachel Schiff, C. Kent Osborne, Jenny C. Chang, Mothaffar Rimawi, Meghana V. Trivedi

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Study Objective To determine if development of acneiform rash is a predictor of objective response rate with lapatinib. Design Subanalysis of data from a prospective, phase II study. Setting Academic breast care clinic. Patients Forty-nine treatment-naïve patients with human epidermal growth factor receptor-2 (HER2)-positive locally advanced breast cancer, who were treated with neoadjuvant lapatinib monotherapy for 6 weeks; 47 patients were included in the final analysis. Measurements and Main Results Of the 49 patients enrolled, 33 (67%) developed a rash of any type, and 26 (55%) had acneiform rash. Of the 26 evaluable patients with acneiform rash (55%), 19 (73%) responded to lapatinib and 7 (27%) did not. Of the 21 evaluable patients without acneiform rash, 11 (67%) responded to treatment and 7 (33%) did not. Thus, no association was found between the occurrence of acneiform rash and response to lapatinib monotherapy. Conclusion This study does not support the development of the acneiform rash as a predictor of clinical efficacy of lapatinib in the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)1126-1129
Number of pages4
JournalPharmacotherapy
Volume33
Issue number10
DOIs
StatePublished - Jan 1 2013

Keywords

  • breast cancer
  • dermatologic toxicity
  • EGFR
  • HER2
  • lapatinib
  • rash

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer'. Together they form a unique fingerprint.

Cite this